Leishmaniasis primary prevention: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Leishmaniasis}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Infectious disease Category:Parasitic diseases [[Category:Tropica..." |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
==Pharmacotherapy== | |||
====Acute Pharmacotherapies==== | |||
Physicians may consult CDC to obtain information on how to treat leishmaniasis. The drug sodium stibogluconate is available under an Investigational New Drug protocol from the CDC Drug Service. | |||
====Chronic Pharmacotherapies==== | |||
==References== | ==References== | ||
Revision as of 17:55, 8 February 2012
|
Leishmaniasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leishmaniasis primary prevention On the Web |
|
American Roentgen Ray Society Images of Leishmaniasis primary prevention |
|
Risk calculators and risk factors for Leishmaniasis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pharmacotherapy
Acute Pharmacotherapies
Physicians may consult CDC to obtain information on how to treat leishmaniasis. The drug sodium stibogluconate is available under an Investigational New Drug protocol from the CDC Drug Service.